Zyla’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Egalet develops, manufactures and commercializes non-narcotic and abuse-discouraging products for the treatment of chronic pain. Read more

Egalet develops, manufactures and commercializes non-narcotic and abuse-discouraging products for the treatment of chronic pain. Read more

Todd Smith's photo - President & CEO of Zyla

President & CEO

Todd Smith

CEO Approval Rating

88/100

Founded:

1995

Status:

PublicOtherZCOR

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Collegium Pharmaceutical is Zyla's biggest rival. Collegium Pharmaceutical was founded in 2003, and is headquartered in Stoughton, Massachusetts. Like Zyla, Collegium Pharmaceutical also works within the Pharmaceuticals sector. Collegium Pharmaceutical generates $218.9M more revenue vs. Zyla.

BDSI is one of Zyla's top competitors. BDSI's headquarters is in Raleigh, North Carolina, and was founded in 1997. Like Zyla, BDSI also works within the Pharmaceuticals sector. BDSI generates 165% of Zyla's revenue.

Scilex is seen as one of Zyla's top competitors. Scilex is a Private company that was founded in 2012 in San Diego, California. Scilex operates in the Pharmaceuticals industry. Compared to Zyla, Scilex has 45 fewer employees.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Zogenix a competitor of Zyla?

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$82.8M

Zyla's revenue is the ranked 6th among it's top 10 competitors. The top 10 competitors average 417M. Over the last two quarters, Zyla's revenue has decreased by 1.2%. Specifically, in Q1 2020's revenue was $19.1M; in Q4 2019, it was $19.3M.

Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Tivorbex

Oct 2018

Source »
undisclosed
TIVORBEX is a nonsteroidal anti-inflammatory drug that provides for the treatment of acute pain for adults.

-

-

Oct 2018

Source »
undisclosed
-
Iroko Pharmaceuticals, LLC

Oct 2018

Source »
undisclosed
ZORVOLEX is a nonsteroidal anti-inflammatory drug that provides for the treatment of acute and osteoarthritis pain.
VIVLODEX

Oct 2018

Source »
undisclosed
VIVLODEX is a nonsteroidal anti-inflammatory drug that provides for the treatment of osteoarthritis pain.
Iroko Pharmaceuticals, LLC

Oct 2018

Source »
undisclosed
Iroko develops, commercializes and markets non-narcotic drugs for pain management.

These are all the companies that Zyla has acquired. Zyla has acquired 5 companies and its latest acquisition was Tivorbex in Oct 2018. TIVORBEX is a nonsteroidal anti-inflammatory drug that provides for the treatment of acute pain for adults.

Zyla Funding History

$27.6M$41.9M$61.9M$112.3M$152.3M$192.3M$234.5M

Since Zyla was founded in 1995, it has participated in 7 rounds of funding. In total Zyla has raised $234.5M. Zyla's last funding round was on Jan 2019 for a total of $42.2M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Jan 2019
$42.2M
-
Debt
Jan 2017
$40M
-
Debt
Aug 2016
$40M
-
IPO
Feb 2014
$50.4M

Equity
Sep 2013
$20M

Total Funding: $234.5M

Since Zyla was founded in 1995, it has participated in 7 rounds of funding. In total Zyla has raised $234.5M. Zyla's last funding round was on Jan 2019 for a total of $42.2M

Investments

No recent investments found related to Zyla

Zyla News

April 30, 2020MarketScreener

to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results on May 15, 2020

(marketscreener.com) WAYNE, Pa., May 1, 2020 /PRNewswire/ -- Zyla Life Sciences , a commercial stage ... See more »
March 27, 2020BioSpace

Zyla Life Sciences Reports Fourth Quarter and Full Year 2019 Financial Results

Zyla Life Sciences (OTCQX: ZCOR) ("Zyla" or the "Company"), a commercial-stage life sciences company,... See more »
March 18, 2020Global Legal Chronicle

Zyla Life Science's Merger With Assertio Therapeutics

Dechert LLP advised Zyla Life Sciences, while Gibson, Dunn & Crutcher LLP acted as legal counsel to A... See more »
March 17, 2020The Business Journals: Philadelphia

Wayne-based drug company enters into $17.5M merger deal

Zyla Life Sciences (OTCQX: ZCOR), a Wayne-based specialty pharmaceutical company that focuses on non-... See more »
December 2, 2019BioPortfolio

Egalet Corp EGLT Financial and Strategic SWOT Analysis Review Published by Global Data Prices from USD $110

Egalet Corp EGLT Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT ... See more »
November 18, 2019Medical Buyer

Zyla Life Sciences Reports Third Quarter 2019 Financial Results

Zyla Life Sciences (OTCQX: ZCOR) ("Zyla" or the "Company"), a commercial-stage life sciences company,... See more »

Zyla Press Releases

April 30, 2018ForImmediateRelease

Egalet Presented Data at American Academy of Pain Medicine Examining the Potential of ARYMO® ER to Deter Opioid Abuse

Travel & Tourism Industry release: WAYNE, Pa., April 30, 2018 /PRNewswire/ - Egalet Corporation (Nasd... See more »
February 1, 2018PR Newswire

Egalet to Participate in Panel at BIO CEO & Investor Conference

WAYNE, Pa., Feb. 1, 2018 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integr... See more »
January 24, 2018ForImmediateRelease

Egalet to Co-Host Category 1 Focus Group

Travel & Tourism Industry release: WAYNE, Pa., Jan. 24, 2018 /PRNewswire/ - Egalet Corporation (Nasda... See more »
November 8, 2017PR Newswire

Egalet Announces Third Quarter 2017 Financial Results

WAYNE, Pa., Nov. 8, 2017 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) (Egalet), a fully integrat... See more »
October 30, 2017PR Newswire

Egalet to Present at Upcoming Scientific and Investor Conferences

WAYNE, Pa., Oct. 30, 2017 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integ... See more »
October 25, 2017PR Newswire

Egalet to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results on November 8, 2017

WAYNE, Pa., Oct. 25, 2017 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integ... See more »
September 6, 2017Blackbird

Egalet to Present at Investor Conferences this Fall

WAYNE, Pa., Sept. 6, 2017 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integ... See more »

Headquarters

600 Lee Road Suite 100

Wayne, Pennsylvania19087

610-833-4200

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Egalet develops, manufactures and commercializes non-narcotic and abuse-discouraging products for the treatment of chronic pain. Zyla was founded in 1995. Zyla's headquarters is located in Wayne, Pennsylvania, USA 19087. It has raised 234.5M in 7 roun...

CEO

Zyla's President & CEO, Todd Smith, currently has an approval rating of 88%. Zyla's primary competitors are Collegium Pharmaceutical, BDSI & Scilex.

Website

egalet.com

Frequently Asked Questions about Zyla

  1. When was Zyla founded?

    Zyla was founded in 1995
  2. Who is Zyla's CEO?

    Zyla's CEO is Todd Smith
  3. How much revenue does Zyla generate?

    Zyla generates $82.8M in revenue
  4. How much funding does Zyla have?

    Zyla has historically raised $234.5M in funding
  1. Where is Zyla's headquarters?

    Zyla's headquarters is in Wayne Pennsylvania, USA
  2. How many employees does Zyla have?

    Zyla has 127 employees
  3. What sector does Zyla operate in?

    Zyla is in Pharmaceuticals
  4. Who are Zyla's competitors?

    Zyla's top competitors are Collegium Pharmaceutical, BDSI, Scilex